Eli Lilly CEO David Ricks discusses GLP-1s and Medicare coverage Medicare’s temporary coverage for obesity GLP-1 drugs has brought roughly 700,000 new senior users since July, with about 70% on Lilly

Eli Lilly CEO David Ricks discusses GLP-1s and Medicare coverage Medicare’s temporary coverage for obesity GLP-1 drugs has brought roughly 700,000 new senior users since July, with about 70% on Lilly medicines. Lilly’s Zepbound remains the main beneficiary, while the oral pill Foundayo is gaining traction as a convenient option. https://www. cnbc.com/2026/09/21/eli-lilly- ceo-david-ricks-glp-1s-me